Your browser doesn't support javascript.
loading
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García, Celina; Rivas, Martín A; Ibrahim, Yasir H; Calvo, María Teresa; Gris-Oliver, Albert; Rodríguez, Olga; Grueso, Judit; Antón, Pilar; Guzmán, Marta; Aura, Claudia; Nuciforo, Paolo; Jessen, Katti; Argilés, Guillem; Dienstmann, Rodrigo; Bertotti, Andrea; Trusolino, Livio; Matito, Judit; Vivancos, Ana; Chicote, Irene; Palmer, Héctor G; Tabernero, Josep; Scaltriti, Maurizio; Baselga, José; Serra, Violeta.
Affiliation
  • García-García C; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Rivas MA; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Ibrahim YH; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Calvo MT; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Gris-Oliver A; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Rodríguez O; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Grueso J; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Antón P; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Guzmán M; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Aura C; Molecular Pathology Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Nuciforo P; Molecular Pathology Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Jessen K; Takeda California, San Diego, CA 92121.
  • Argilés G; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
  • Dienstmann R; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
  • Bertotti A; Department of Oncology, University of Torino School of Medicine, 10060 Candiolo, Torino, Italy.
  • Trusolino L; Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, 10060 Candiolo, Torino, Italy.
  • Matito J; Department of Oncology, University of Torino School of Medicine, 10060 Candiolo, Torino, Italy.
  • Vivancos A; Translational Cancer Medicine, Candiolo Cancer Institute - FPO IRCCS, 10060 Candiolo, Torino, Italy.
  • Chicote I; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Palmer HG; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Tabernero J; Stem Cells and Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Scaltriti M; Stem Cells and Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Baselga J; Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035-Barcelona, Spain.
  • Serra V; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Clin Cancer Res ; 21(24): 5499-5510, 2015 Dec 15.
Article in En | MEDLINE | ID: mdl-26272063

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Tumor Suppressor Protein p53 / Protein Kinase Inhibitors / Mutation / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Spain

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Tumor Suppressor Protein p53 / Protein Kinase Inhibitors / Mutation / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Spain